Clinical Guideline Highlights for the Hospitalist: Focused Updates to Pediatric Asthma Management

2021 ◽  
Vol October 2021 - Online First ◽  
Author(s):  
Michelle D Veters ◽  
Adolfo L Molina
Keyword(s):  
Expert Panel ◽  
Asthma Management ◽  
Target Population ◽  
National Institutes Of Health ◽  
Recurrent Wheezing ◽  
Blood Institute ◽  
National Heart Lung ◽  
Children With Asthma ◽  
Health Target ◽  
Adults And Children

GUIDELINE TITLE: 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC) Expert Panel Working Group1 RELEASE DATE: Online: December 3, 2020 PRIOR VERSIONS: 1991, 1997, 2002, 2007 DEVELOPER: NAEPPCC Expert Panel Working Group (referred to as “the Expert Panel”) of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health FUNDING SOURCE: NHLBI of the National Institutes of Health TARGET POPULATION: Adults and children with asthma and recurrent wheezing

Stepping Up the Treatment of Children With Asthma

PEDIATRICS ◽  
1993 ◽  
Vol 92 (1) ◽  
pp. 144-146
Author(s):  
CLIFTON T. FURUKAWA
Keyword(s):  
Expert Panel ◽  
Inhaled Corticosteroids ◽  
Asthma Management ◽  
Objective Measures ◽  
Pharmacologic Therapy ◽  
Asthma Morbidity ◽  
Blood Institute ◽  
National Heart Lung ◽  
Children With Asthma ◽  
Environmental Measures

In response to the increase in asthma morbidity and mortality noted in the 1980s, the National Heart, Lung, and Blood Institute convened an expert panel and published its recommendations as the National Asthma Education Program in 1991.1 Comprehensive guidelines were developed focusing on four components of asthma management: 1. Objective measures of lung function 2. Pharmacologic therapy 3. Environmental measures to control allergens and irritants 4. Patient education This commentary addresses issues related to pharmacologic therapy. The guidelines of this component of asthma management focus on treatment of inflammation, rather than on bronchodilation. Because corticosteroids are the most effective anti-inflammatory agents used to treat asthma, there has been a shift to using inhaled corticosteroids.

scholarly journals Mentoring upcoming researchers for non-communicable diseases’ research and practice in Malawi

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Adamson S. Muula ◽  
Mina C. Hosseinipour ◽  
Martha Makwero ◽  
Johnstone Kumwenda ◽  
Prosper Lutala ◽  
...  
Keyword(s):  
Research Capacity ◽  
Communicable Diseases ◽  
Lessons Learned ◽  
National Institutes Of Health ◽  
Non Communicable Diseases ◽  
Mentorship Program ◽  
Research And Practice ◽  
Blood Institute ◽  
Research Mentorship ◽  
National Heart Lung

AbstractThe Malawi College of Medicine and its partners are building non-communicable diseases’ (NCDs’) research capacity through a grant from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health. Several strategies are being implemented including research mentorship for junior researchers interested to build careers in NCDs’ research. In this article, we present the rationale for and our experiences with this mentorship program over its 2 years of implementation. Lessons learned and the challenges are also shared.

scholarly journals National Institutes of Health Funding for Tobacco Control: 2006 and 2016

2018 ◽  
Vol 33 (2) ◽  
pp. 279-284
Author(s):  
Ashley L. Merianos ◽  
Judith S. Gordon ◽  
Kelsi J. Wood ◽  
E. Melinda Mahabee-Gittens
Keyword(s):  
Tobacco Control ◽  
Secondary Analysis ◽  
National Institutes Of Health ◽  
Fiscal Year ◽  
Topic Area ◽  
Study Objective ◽  
Frequency Distributions ◽  
Blood Institute ◽  
National Heart Lung ◽  
Nih Funding

Purpose: The study objective was to describe and compare changes in newly funded National Institutes of Health (NIH) tobacco-related awards between fiscal year (FY) 2006 and FY2016. Design: Secondary analysis of NIH data. Setting: National Institutes of Health Research Portfolio Online Reporting Tool database was used. Subjects: National Institutes of Health tobacco-related awards newly funded during FY2006 and FY2016. Measures: Search terms included tobacco, smoking, nicotine, secondhand smoke, and e-cigarettes. Grants and funding amounts were retrieved. Analysis: We calculated frequency distributions to determine the number and percentage of total NIH grants funded overall and by specific institute, and inflation-adjusted total and median funding amounts. We computed percentage differences in number of new grants, funding amounts, and percentage of funding allocated overall, and by institute. Results: There was a 187% increase in the percentage of total NIH funding allocated to new tobacco-related awards from 0.09% in FY2006 to 0.25% in FY2016. Total number of awards increased by 67% in FY2016 (n = 144; $56 015 931) compared to FY2006 (n = 86; $22 076 987), and there was a 154% increase in inflation-adjusted total funding for tobacco control. The top funding institutes were National Institute on Drug Abuse and National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism was third in FY2006; and National, Heart, Lung and Blood Institute in FY2016. Research grants were the most frequently funded. Smoking cessation was a common topic area and increased by 64%. Conclusion: NIH funding is critical for advancing the science of nicotine and tobacco research.

scholarly journals The role of data and safety monitoring boards in implementation trials: When are they justified?

2020 ◽  
Vol 4 (3) ◽  
pp. 229-232
Author(s):  
Kevin Fiscella ◽  
Mechelle Sanders ◽  
Tameir Holder ◽  
Jennifer K. Carroll ◽  
Amneris Luque ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Safety Monitoring ◽  
National Institutes Of Health ◽  
Phase Iii ◽  
Blood Institute ◽  
Phase Iii Clinical Trials ◽  
National Heart Lung ◽  
Cooperative Agreements ◽  
Monitor Data

AbstractThe National Institutes of Health requires data and safety monitoring boards (DSMBs) for all phase III clinical trials. The National Heart, Lung and Blood Institute requires DSMBs for all clinical trials involving more than one site and those involving cooperative agreements and contracts. These policies have resulted in the establishment of DSMBs for many implementation trials, with little consideration regarding the appropriateness of DSMBs and/or key adaptations needed by DSMBs to monitor data quality and participant safety. In this perspective, we review the unique features of implementation trials and reflect on key questions regarding the justification for DSMBs and their potential role and monitoring targets within implementation trials.

Sign in / Sign up

Export Citation Format

Share Document